

Epidermolysis Bullosa Market to Observe Impressive Growth by (2024-2034), Evaluates DelveInsight

DelveInsight's Epidermolysis Bullosa Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

NEVADA, LAS VEGAS, UNITED STATES, June 3, 2024 /EINPresswire.com/ -- The Epidermolysis Bullosa market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epidermolysis Bullosa pipeline products will significantly revolutionize the Epidermolysis Bullosa market dynamics.



Epidermolysis Bullosa Market Forecast

DelveInsight's "Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Epidermolysis Bullosa, historical and forecasted epidemiology as well as the Epidermolysis Bullosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Epidermolysis Bullosa market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Epidermolysis Bullosa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Epidermolysis Bullosa Market Forecast](#)

Some of the key facts of the Epidermolysis Bullosa Market Report:

The Epidermolysis Bullosa market size was valued at ~USD 1,700 Million in the year 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

In 2023, the Epidermolysis Bullosa market size in the US, among the seven major markets (7MM),

reached approximately USD 1,300 million, marking the highest figure. It is projected to undergo further growth by 2034.

In 2023, the United States had the highest prevalence of Epidermolysis Bullosa cases, making up approximately 65% of the total cases among the seven major markets (7MM). Meanwhile, the EU4 countries and the UK comprised around 30%, and Japan accounted for approximately 5% of the total population share in the same year.

As per DelveInsight's projections, approximately 18,000 cases of Epidermolysis Bullosa simplex, 1,450 cases of junctional Epidermolysis Bullosa, and 8,500 cases of dystrophic Epidermolysis Bullosa were reported in the United States in 2023.

Key Epidermolysis Bullosa Companies: Krystal Biotech, Chiesi Farmaceutici, Abeona Therapeutics, Castle Creek Biosciences, Krystal Biotech, Castle Creek Biosciences, RegeneRx/Lenus Therapeutics, and others

Key Epidermolysis Bullosa Therapies: VYJUVEK (beremagene geperpavec), FILSUVEZ (oleogel-S10), EB-101, D-Fi (dabocemagene autotoficel), B-VEC, FCX-007, RGN-137, and others

Epidermolysis Bullosa Overview

Epidermolysis Bullosa (EB) is a group of rare genetic disorders characterized by fragile skin that blisters and forms painful sores in response to minor friction or trauma. This condition is caused by mutations in genes responsible for producing proteins that help anchor the layers of the skin together.

Get a Free sample for the Epidermolysis Bullosa Market Report:

https://www.delveinsight.com/report-store/epidermolysis-bullosa-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Epidermolysis Bullosa Market

The dynamics of the Epidermolysis Bullosa market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

"In June 2022, the European Commission (EC) approved FILSUVEZ for the treatment of partial-thickness wounds associated with dystrophic and junctional epidermolysis bullosa in patients six months and older"

Epidermolysis Bullosa Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Epidermolysis Bullosa Epidemiology Segmentation:

The Epidermolysis Bullosa market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

Total Prevalence of Epidermolysis Bullosa
Prevalent Cases of Epidermolysis Bullosa by severity
Gender-specific Prevalence of Epidermolysis Bullosa
Diagnosed Cases of Episodic and Chronic Epidermolysis Bullosa

Download the report to understand which factors are driving Epidermolysis Bullosa epidemiology trends @ [Epidermolysis Bullosa Epidemiological Insights](#)

Epidermolysis Bullosa Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epidermolysis Bullosa market or expected to get launched during the study period. The analysis covers Epidermolysis Bullosa market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Epidermolysis Bullosa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Epidermolysis Bullosa Therapies and Key Companies

VYJUVEK (beremagene geperpavec): Krystal Biotech
FILSUVEZ (oleogel-S10): Chiesi Farmaceutici
EB-101: Abeona Therapeutics
D-Fi (dabocemagene autoficel): Castle Creek Biosciences
B-VEC: Krystal Biotech
FCX-007: Castle Creek Biosciences
RGN-137: RegeneRx/ Lenus Therapeutics

Epidermolysis Bullosa Market Drivers

The rise in the prevalence of epidermolysis bullosa
Robust clinical pipeline containing emerging drugs with novel RoA and MoA
Gene and cell therapies are also in the clinical stages of development for the treatment of epidermolysis bullosa
Increase funding support from organizations such as epidermolysis bullosa Research Partnership

Epidermolysis Bullosa Market Unmet Needs

Challenges in diagnosis
Lack of effective treatment
Challenges in the clinical trial

Poor disease understanding

Scope of the Epidermolysis Bullosa Market Report

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Epidermolysis Bullosa Companies: Krystal Biotech, Chiesi Farmaceutici, Abeona Therapeutics, Castle Creek Biosciences, Krystal Biotech, Castle Creek Biosciences, RegeneRx/Lenus Therapeutics, and others

Key Epidermolysis Bullosa Therapies: VYJUVEK (beremagene geperpavec), FILSUVEZ (oleogel-S10), EB-101, D-Fi (dabocemagene autoficel), B-VEC, FCX-007, RGN-137, and others

Epidermolysis Bullosa Therapeutic Assessment: Epidermolysis Bullosa current marketed and Epidermolysis Bullosa emerging therapies

Epidermolysis Bullosa Market Dynamics: Epidermolysis Bullosa market drivers and Epidermolysis Bullosa market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Epidermolysis Bullosa Unmet Needs, KOL's views, Analyst's views, Epidermolysis Bullosa Market Access and Reimbursement

Discover more about therapies set to grab major Epidermolysis Bullosa market share @ [Epidermolysis Bullosa Treatment Landscape](#)

Table of Contents

1. Epidermolysis Bullosa Market Report Introduction
2. Executive Summary for Epidermolysis Bullosa
3. SWOT analysis of Epidermolysis Bullosa
4. Epidermolysis Bullosa Patient Share (%) Overview at a Glance
5. Epidermolysis Bullosa Market Overview at a Glance
6. Epidermolysis Bullosa Disease Background and Overview
7. Epidermolysis Bullosa Epidemiology and Patient Population
8. Country-Specific Patient Population of Epidermolysis Bullosa
9. Epidermolysis Bullosa Current Treatment and Medical Practices
10. Epidermolysis Bullosa Unmet Needs
11. Epidermolysis Bullosa Emerging Therapies
12. Epidermolysis Bullosa Market Outlook
13. Country-Wise Epidermolysis Bullosa Market Analysis (2020–2034)
14. Epidermolysis Bullosa Market Access and Reimbursement of Therapies
15. Epidermolysis Bullosa Market Drivers
16. Epidermolysis Bullosa Market Barriers
17. Epidermolysis Bullosa Appendix
18. Epidermolysis Bullosa Report Methodology
19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/716921362>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.